Cargando…

Amyloid pathology arrangements in Alzheimer’s disease brains modulate in vivo seeding capability

Amyloid-β (Aβ) misfolding is one of the hallmark pathological features of Alzheimer’s disease (AD). AD can manifest with diverse symptomatology including variable rates of cognitive decline, duration of clinical disease, and other detrimental changes. Several reports suggest that conformational dive...

Descripción completa

Detalles Bibliográficos
Autores principales: Duran-Aniotz, Claudia, Moreno-Gonzalez, Ines, Gamez, Nazaret, Perez-Urrutia, Nelson, Vegas-Gomez,, Laura, Soto, Claudio, Morales, Rodrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008576/
https://www.ncbi.nlm.nih.gov/pubmed/33785065
http://dx.doi.org/10.1186/s40478-021-01155-0
Descripción
Sumario:Amyloid-β (Aβ) misfolding is one of the hallmark pathological features of Alzheimer’s disease (AD). AD can manifest with diverse symptomatology including variable rates of cognitive decline, duration of clinical disease, and other detrimental changes. Several reports suggest that conformational diversity in misfolded Aβ is a leading factor for clinical variability in AD, analogous to what it has been described for prion strains in prion diseases. Notably, prion strains generate diverse patterns of misfolded protein deposition in the brains of affected individuals. Here, we tested the in vivo prion-like transmission features of four AD brains displaying particular patterns of amyloidosis. AD brains induced different phenotypes in recipient mice, as evaluated by their specific seeding activity, as well as the total amount of Aβ deposited surrounding vascular structures and the reactivity of amyloid pathology to thioflavin S. Our results support the notion that AD-subtypes are encoded in disease-associated Aβ. Further research exploring whether AD include a spectrum of different clinical conditions or syndromes may pave the way to personalized diagnosis and treatments. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-021-01155-0.